个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Real-world effectiveness of mitoxantrone hydrochloride liposome containing regimens in acute myeloid leukemia

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Gong Tie-Jun[1] * ; Li Wei-Ming[2] ; Liu Li[3] ; Chen Yu-Qing[4] ; Gao Su-Jun[5] ; Yang Wei[6] ; Zhu Xiao-Yu[7] ; Deng Jian-Chuan[8] ; Liu Yan[9] ; Zhang Jing-Yu[10] ; Ge Xiao-Yan[11] ; Li Hui[12] ; Wang Xiao-Gang[13] ; Bai Yuan-Song[14] ; Tan Xiao-Hong[15] ; Zhang Yi-Cheng[16] ; He Peng-Cheng[17] ; Ma Jun-Jie[18] ; Yang Yan-Li[19] ; Feng Yu-Hu[20] ; Wei Xu-Dong[21] ; Li Jian-Yong[22] ; Fan Lei[22] ; Xu Hong-Zhi[23] ; Wang Hong-Xiang[24] ; Yan Xiao-Jing[25] ; Zhou Ze-Ping[26] ; Zhong Hua[27] ; Zhang Ying[28] ; Ma Jun[1] ;
机构： [1]Harbin Institute of Hematology & Oncology, Harbin the First Hospital, Harbin, 150010, China. [2]Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. [3]Department of Hematology, Tangdu Hospital, Xi 'an, 710038, China. [4]Department of Hematology, Henan Provincial People's Hospital, Zhengzhou, 450003, China. [5]Department of Hematology, The First Bethune Hospital of Jilin University, Changchun, 130021, China. [6]Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, 110004, China. [7]Department of Hematology, Anhui Provincial Hospital, Hefei, 230001, China. [8]Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China. [9]Department of Hematology, Zibo Central Hospital, Zibo, 250036, China. [10]Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China. [11]Department of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, 030001, China. [12]Department of Hematology, Sichuan Provincial People's Hospital, Chengdu, 610072, China. [13]Department of Hematology, Zhejiang Provincial People's Hospital, Hangzhou, 310014, China. [14]Department of Oncology, The Third Bethune Hospital of Jilin University, Changchun, 130033, China. [15]Department of Lymphatic Hematology and Pediatric Oncology, Guangxi Medical University Cancer Hospital, Nanning, 530200, China. [16]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. [17]Department of Hematology, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, 710061, China. [18]Department of Hematology, Yantai Yuhuangding Hospital, Yantai, 264000, China. [19]Department of Hematology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233004, China. [20]Department of Hematology, Fuyang People's Hospital, Fuyang, 236001, China. [21]Department of Hematology, Henan Cancer Hospital, Zhengzhou, 450003, China. [22]Department of Hematology, Jiangsu Province Hospital, Nanjing, 210029, China. [23]Department of Hematology, Shandong Provincial Hospital, Jinan, 250021, China. [24]Department of Hematology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, China. [25]Department of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China. [26]Department of Hematology, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650101, China. [27]Department of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China. [28]Department of Hematology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China.
出处：
DOI： 10.1093/oncolo/oyaf304
ISSN：

关键词： acute myeloid leukemia mitoxantrone hydrochloride liposome newly diagnosed acute myeloid leukemia relapsed/refractory acute myeloid leukemia composite complete remission

摘要：
Mitoxantrone hydrochloride liposome (Lipo-MIT) exhibits encouraging efficacy in treating multiple hematologic malignancies. This study evaluated the real-world efficacy and safety of Lipo-MIT-containing regimens in the treatment of acute myeloid leukemia (AML).This noninterventional, ambispective cohort study was conducted at 42 centers in China. Patients with newly diagnosed or relapsed/refractory AML who received Lipo-MIT-containing regimens were included. The primary endpoint was the composite complete remission (CRc) rate.Between January 2022 and December 2023, 117 patients with newly diagnosed AML and 122 patients with relapsed/refractory AML were included. The CRc and objective response rates were 84.6% (95% confidence interval [CI], 76.8-90.6) and 91.5% (95% CI, 84.8-95.8), respectively, in the newly diagnosed AML, and 45.1% (95% CI, 36.1-54.3) and 55.7% (95% CI, 46.5-64.7), respectively, in relapsed/refractory AML. The 2-year-event-free survival and overall survival rates for newly diagnosed AML were 67.0% (95% CI, 54.4-76.8) and 77.8% (95% CI, 63.8-86.9), respectively, while the rates for relapsed/refractory AML were 23.9% (95% CI, 12.5-37.3) and 56.9% (95% CI, 39.6-70.9), respectively. Univariate and multivariate analyses suggested age and the number of prior failed induction therapy cycles as independent prognostic factors for CRc in relapsed/refractory AML (all P < .05). Treatment-related adverse events (AEs) were reported in 216 patients (90.4%). Thrombocytopenia (64.4%), leukopenia (63.6%), and neutropenia (60.7%) were the most common AEs of grade 3-4. No treatment-related deaths occurred.Lipo-MIT-containing regimens were effective and well-tolerated in AML under real-world circumstances.ChiCTR2200067172.© The Author(s) 2025. Published by Oxford University Press.

语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学
最新[2025]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学
JCR分区：
出版当年[2024]版：
Q2 ONCOLOGY
最新[2024]版：
Q2 ONCOLOGY

影响因子： 最新[2024版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2024版]

第一作者：
第一作者机构： [1]Harbin Institute of Hematology & Oncology, Harbin the First Hospital, Harbin, 150010, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Gong Tie-Jun,Li Wei-Ming,Liu Li,et al.Real-world effectiveness of mitoxantrone hydrochloride liposome containing regimens in acute myeloid leukemia[J].The Oncologist.2025,30(10):doi:10.1093/oncolo/oyaf304.
APA：
Gong Tie-Jun,Li Wei-Ming,Liu Li,Chen Yu-Qing,Gao Su-Jun...&Ma Jun.(2025).Real-world effectiveness of mitoxantrone hydrochloride liposome containing regimens in acute myeloid leukemia.The Oncologist,30,(10)
MLA：
Gong Tie-Jun,et al."Real-world effectiveness of mitoxantrone hydrochloride liposome containing regimens in acute myeloid leukemia".The Oncologist 30..10(2025)

相关文献

[1]American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. [2]Ivosidenib in Chinese patients with relapsed or refractory isocitrate dehydrogenase 1 mutated acute myeloid leukemia: a registry study [3]Venetoclax plus modified-intensity Idarubicin and Cytarabine treatment as first-line treatment for newly diagnosed pediatric acute myeloid leukemia [4]Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission [5]The modified melphalan and busulfan-based regimen combined with maintenance therapy improved the survival of patients with refractory/relapsed AML after allogeneic transplantation: middle-term outcome of a multicenter trial [6]A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer [7]Glycolysis and chemoresistance in acute myeloid leukemia [8]Targeting PRAME for acute myeloid leukemia therapy [9]Phase I dose escalation and pharmacokinetics clinical trial of mitoxantrone hydrochloride liposome in children with relapsed and refractory solid tumors [10]Structural maintenance of chromosomes 4 is required for leukemia stem cell maintenance in MLL-AF9 induced acute myeloid leukemia.

资源点击量：65780 今日访问量：3 总访问量：5151 更新日期：2025-12-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号